◈ Nootpedia
Compact view
Research pass: medium Pharmaceutical · Oral SKIP-FOR-NOW HIGH

Fladrafinil

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW HIGH

Lafon CRL-series compound that never advanced past 1970s-80s animal pharmacology — zero published human trials, zero established human safety profile, zero validated dosing. Modafinil is strictly better on every metric (cheap, abundant clinical data, established sourcing, known interactions). Verdict would change only if (a) someone publishes an actual human PK/PD study on fladrafinil AND (b) modafinil sourcing collapses globally — currently inverted.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-FOR-NOW

    Modafinil 100 mg AM via Indian pharmacy is strictly dominant — established human PK/PD, 25+ years of safety data, cheap, reliable supply, known interactions. Fladrafinil offers no validated benefit and adds substantial unknown-unknowns to a 20yo brain that Dylan has explicitly named his most valuable asset. The "calmer, less anxiogenic" pitch is anecdote; the brain-development risk profile is unmeasured. Modafinil is the rational pick.

  • 30-50, executive maintenance
    SKIP-FOR-NOW

    Same logic. Even cleaner Rx access via US telehealth. No reason to choose an uncharacterized prodrug.

  • 50+, mild cognitive decline
    SKIP-FOR-NOW

    Higher baseline hepatic vulnerability + medication burden = an undocumented hepatic-prodrug compound is a worse fit, not a better one. Use modafinil with LFT monitoring; donepezil/rivastigmine for disease-specific use cases.

  • Anxiety-prone
    SKIP-FOR-NOW

    The "anti-anxiety / calmer focus" pitch is appealing for this archetype but unsupported by human evidence. If modafinil's anxiogenic edge is intolerable, better-characterized alternatives include selegiline, bromantane, or pitolisant — all with human safety data.

  • High athletic load, tested status
    SKIP-FOR-NOW

    Likely WADA-banned by structural analogy to modafinil even though fladrafinil itself isn't explicitly listed (S6 catch-all language for "and other substances with similar chemical structure or biological effect"). Tested athletes have no use case.

  • Sleep-disordered
    SKIP-FOR-NOW

    Modafinil/armodafinil/solriamfetol/pitolisant are FDA-approved with characterized safety profiles. Fladrafinil offers nothing useful.

  • Recovery-focused (post-injury, post-illness)
    SKIP-FOR-NOW

    Adding undocumented hepatic load to a body in recovery is the wrong direction.

  • Strength/anabolic-focused
    NOT-RELEVANT

    No anabolic effect; presumed modafinil-class appetite suppression interferes with bulking phases. Universal verdict: Fladrafinil is dominated by modafinil for every user archetype. There is no preference profile under which fladrafinil wins.

▸ Subjective experience (deep)

The honest answer: nobody actually knows. What follows is a synthesis of forum reports, with the caveat that none of these have been validated against clinical instruments.

Onset: Reportedly ~45-90 minutes orally, similar to or slightly slower than adrafinil. The conversion delay is presumed.

Peak: ~2-4 hours.

Duration: Reportedly 8-12+ hours; some users describe a longer plateau than modafinil at equivalent dose. Possibly an artifact of the bisfluoro modification slowing clearance, possibly reporting bias.

Characteristic effects (per user reports):

  • Wakefulness without the "edge" some users get from modafinil
  • Reduced motivation to socialize / chat (consistent with modafinil's task-focus profile)
  • Mood neutralization — less affect, less reactivity (the "anti-aggression" extrapolation from mouse data)
  • Reduced appetite (presumed modafinil-class effect)
  • Mild HR / BP elevation (presumed modafinil-class effect)

Honest variability: Higher than modafinil's already-substantial variability, because nobody has standardized the dose-response and there is no pharmaceutical-grade reference compound. Two users on "30 mg fladrafinil" may not be on the same compound, the same purity, or even the same dose actually delivered.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Presumed minimal (modafinil-class) but unverified. Possibly different given altered clearance kinetics.
  • Recommended cycle: Don't. If used despite the SKIP recommendation, mirror modafinil's 5-on, 2-off pattern with mandatory LFT monitoring — but the better protocol is "take modafinil instead."
  • Reset protocol: N/A — no data.
▸ Stacking deep dive

Synergistic with

  • N/A — once converted (assuming the prodrug hypothesis is correct), the synergy profile would be modafinil's (l-theanine, citicoline, rhodiola, bromantane, selegiline). But there is no rationale for choosing fladrafinil as the substrate when modafinil is cleaner, cheaper, and better-characterized.

Avoid stacking with

  • Other hepatotoxic compounds — alcohol, high-dose acetaminophen, statins, methotrexate, isoniazid, kava, comfrey, high-dose niacin. The presumed adrafinil-class hepatic load makes additive toxicity a concern.
  • CYP3A4 inducers/inhibitors — would unpredictably alter conversion to active metabolite. With no human PK data, the direction of the interaction is unpredictable.
  • Hormonal contraceptives — assumed CYP3A4 induction (modafinil-class) reduces efficacy; same partner-relevant caveat.
  • Other research-chem eugeroics (hydrafinil, flmodafinil, etc.) — combining undocumented compounds compounds the unknown safety surface.

Neutral / safe co-administration

  • Cannot reliably define. Without characterized drug-interaction profile, "neutral" is inference, not knowledge.
▸ Drug interactions deep dive

Presumed (by modafinil-class extrapolation):

  • CYP3A4 induction → reduced hormonal contraceptive efficacy, reduced opioid analgesia, reduced levels of CYP3A4-substrate medications.
  • Mild CYP2C19 inhibition → possibly elevated phenytoin, diazepam, omeprazole levels.
  • Hepatic load additive with other hepatotoxins (alcohol, acetaminophen, AAS, methylated supplements).

Documented (in humans): None.

▸ Pharmacogenomics
  • CYP3A4 / CYP3A5 — presumed to affect conversion rate (adrafinil-class).
  • CYP2C19 — presumed to affect active metabolite clearance.
  • HLA-B alleles — SJS-susceptibility unknown for fladrafinil specifically.
  • For Dylan: Awaiting 23andMe results in June 2026. Even with full pharmacogenomic data, there is no rational reason to apply it to a compound with no human PK/PD baseline. Use modafinil and benefit from genuine PGx-modafinil data.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Research-chem vendor Various US/EU online $25-50 / 30 caps (~30-100 mg each, dosing inconsistent across vendors) Low Variable purity. Sciencebio (defunct), NewMind (defunct as of 2023), various rotating vendors as of 2026. Quality control essentially absent.
Bulk powder International research-chem $50-150 / gram Low Even less consistent than capsules. Requires precise milligram scale and capsule-filling for any reasonable dosing.
Indian pharmacy None N/A N/A No pharmaceutical-grade source exists in any jurisdiction.
Rx anywhere None N/A N/A Never approved for clinical use.

Bottom line on sourcing: Fladrafinil is a research-chem-only compound in 2026 with rotating, unreliable vendor supply, no purity testing standard, and no pharmaceutical alternative. Modafinil sourcing (Indian pharmacy via ModafinilXL or similar, $0.50-1.50/pill, WHO-GMP Sun Pharma source) is dramatically cleaner.

▸ Biomarkers to track (deep)

If used despite the universal SKIP recommendation, mirror the adrafinil monitoring protocol (since the closest analog with documented hepatotoxicity is adrafinil):

Baseline (before starting)

  • ALT, AST, GGT, alkaline phosphatase, total bilirubin, albumin (full LFT panel)
  • Hepatitis B/C serology
  • Resting HR + BP (3-day morning average)
  • Skin photographic baseline (week 1-8 SJS-class watch)
  • Anxiety baseline (GAD-7 or daily VAS)

During use

  • Week 4: full LFT panel — stop drug if ALT or AST >3× ULN, or any clinical symptoms (RUQ pain, jaundice, dark urine, persistent fatigue).
  • Week 12: full LFT panel — same threshold.
  • Quarterly thereafter: full LFT panel.
  • Weeks 1-12: daily skin check (extended past modafinil's 8-week window because no surveillance data exists for fladrafinil specifically).

Post-cycle

  • LFT recheck 6-8 weeks after discontinuation.
▸ Controversies / open debates Live debate

1. "Fladrafinil is a cleaner modafinil — calmer, longer, less anxiogenic"

  • Forum claim: Subjective reports converge on this characterization.
  • Reality: Possibly true, possibly placebo, possibly under-dosing relative to modafinil-equivalent. With zero clinical PK/PD data, the claim is unfalsifiable. Even if true subjectively, the safety unknowns dominate the decision.

2. "The bisfluoro modification means lower mg / better BBB penetration / longer duration"

  • Vendor / forum claim: Yes — citing increased lipophilicity from para-fluoro substitution.
  • Reality: Plausible chemistry, unverified pharmacology. Lipophilicity changes also affect tissue distribution, off-target binding, and metabolic pathways unpredictably. Without human PK data, the claim is structural inference.

3. "Anti-aggression effect makes fladrafinil ideal for combat-sport / high-stress users"

  • Forum claim: Extrapolated from a 1980s mouse aggression study.
  • Reality: A single mouse-model finding does not translate to human behavioral neuroscience. The "calming stim for fighters" pitch is marketing flair, not pharmacology.

4. "Why didn't Lafon develop fladrafinil if it was promising?"

  • Counter-narrative in some nootropic circles: Commercial reasons / Lafon focused on modafinil for IP reasons.
  • Actual record: Lafon's CRL series produced dozens of analogs in the 1970s-80s; modafinil (CRL-40,476) won on a combination of efficacy, tolerability, and developability. The other compounds in the series — including adrafinil and fladrafinil — were shelved because they did not offer compelling differentiation in animal studies relative to modafinil. The "promising compound suppressed by big pharma" narrative is unsupported by the development record.

5. "Research-chem availability makes it the only legal option"

  • Historical edge case: True for some users in 2015-2020 when modafinil sourcing was harder.
  • Current reality (2026): Indian pharmacy modafinil sourcing is routine, US telehealth Rx is straightforward, and the legal-access argument has collapsed.
▸ Verdict change log
  • 2026-05-06 — Initial verdict: SKIP-FOR-NOW / HIGH CONFIDENCE / MEDIUM-priority research pass. Universal SKIP across all archetypes due to (a) zero published human trials, (b) zero established human safety profile, (c) modafinil's strict dominance on every metric, and (d) Dylan's explicit brain-priority making undocumented compounds a bad fit. Verdict would only change if (i) a controlled human PK/PD study published AND (ii) modafinil sourcing globally collapsed — currently inverted scenarios.
▸ Open questions / gaps Open
  1. Zero human PK data. The single most important gap. Without plasma fladrafinil → bisfluoro-modafinil conversion data in humans, every claim about dosing, duration, and interaction is inference.
  2. No published human safety surveillance. Hepatic, dermatologic, and cardiovascular profiles all unknown.
  3. No comparator trial against modafinil or adrafinil. The "calmer / less anxiogenic" claim is unfalsifiable without head-to-head data.
  4. Mouse anti-aggression study replication status unclear. The 1980s Lafon finding has not been extended in modern animal behavioral neuroscience.
  5. WADA classification ambiguous. Likely banned by S6 catch-all language but never explicitly listed.
  6. What would change the verdict? Nothing realistic in the 2026-2027 timeframe. A published phase 1 PK/PD study + cleaner pharmaceutical-grade sourcing + a specific use case where fladrafinil's putative differences (longer duration, lower anxiety) actually beat modafinil for a definable archetype. None of these are currently in motion.
▸ Sources (full, with our context)
Back to compact view